Apigenin and other flavonoids are capable of modulating EGFR, an attractive therapeutic target, by inhibiting Axl mRNA and protein expression, as well as Axl promoter activity, in NSCLC cells (A549, NCI-H460) [211,219]. This evidence concerns the gene AXL and non-small cell lung carcinoma.